Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 13,038 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 13,038 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total transaction of $26,858.28. Following the transaction, the chief financial officer now owns 672,186 shares in the company, valued at $1,384,703.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Checkpoint Therapeutics Trading Up 4.4 %

CKPT stock opened at $2.15 on Friday. Checkpoint Therapeutics, Inc. has a 1 year low of $1.30 and a 1 year high of $3.62. The company has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $1.93. The firm has a market cap of $76.73 million, a PE ratio of -0.78 and a beta of 1.13.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.04. As a group, analysts forecast that Checkpoint Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Checkpoint Therapeutics in a research note on Monday, June 24th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $22.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in Checkpoint Therapeutics by 92.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock worth $26,000 after acquiring an additional 5,375 shares during the last quarter. Choreo LLC acquired a new position in Checkpoint Therapeutics during the 4th quarter worth $44,000. Magnus Financial Group LLC acquired a new position in Checkpoint Therapeutics during the 4th quarter worth $55,000. Lindbrook Capital LLC acquired a new position in Checkpoint Therapeutics during the 1st quarter worth $62,000. Finally, B. Riley Wealth Advisors Inc. lifted its position in Checkpoint Therapeutics by 9.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 49,150 shares of the company’s stock worth $84,000 after acquiring an additional 4,205 shares during the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.